Xencor, Inc Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss
Xencor, Inc (XNCR) reported Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss of $37.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Income Statement › Other Income
us-gaap:MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments · last filed 2025-02-27
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2020-12-31 was $0.00.
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2020-09-30 was $0.00.
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2016-12-31 was -$1.00K, a 200.00% decline year-over-year.
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for the quarter ending 2016-09-30 was $3.00K.
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2024 was $37.00K.
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2023 was $0.00.
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2022 was $0.00.
- Xencor, Inc marketable securities, realized gain (loss), excluding other-than-temporary impairment loss for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 3 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 6 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 9 month | Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment Loss 12 month |
|---|---|---|---|---|
| 2024-12-31 | $37.00K 10-K · filed 2025-02-27 | |||
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-02-27 | |||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $0.00 derived: sum of 2 quarters · filed 2023-02-27 | $153.00K 10-K · filed 2023-02-27 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $153.00K 10-Q · filed 2021-11-08 | ||
| 2020-06-30 | $153.00K 10-Q · filed 2021-08-04 | |||
| 2018-12-31 | -$74.00K 10-K · filed 2021-02-24 | |||
| 2016-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $2.00K derived: sum of 2 quarters · filed 2019-02-26 | $2.00K derived: sum of 3 quarters · filed 2019-02-26 | $5.00K 10-K · filed 2019-02-26 |
| 2016-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $3.00K derived: sum of 2 quarters · filed 2017-11-08 | $6.00K 10-Q · filed 2017-11-08 | $7.00K derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $3.00K 10-Q · filed 2017-08-07 | $4.00K derived: sum of 3 quarters · filed 2018-02-28 | |
| 2016-03-31 | $3.00K 10-Q · filed 2017-05-10 | $4.00K derived: sum of 2 quarters · filed 2018-02-28 | ||
| 2015-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-28 | $5.00K 10-K · filed 2018-02-28 | ||
| 2015-09-30 | $4.00K 10-Q · filed 2016-11-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |